Affective symptoms and cognitive functions in Parkinson's disease

Poletti, Michele; Rosa, Anna De; Bonuccelli, Ubaldo

doi:10.1016/j.jns.2012.02.022

Cited by 57 publications

(49 citation statements)

References 78 publications

(96 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Nonmotor symptoms, including cognitive impairment and affective disorders, are common features in PD and have been shown to be a major determinant of quality of life of PD patients and their caregivers (39,40). The mesolimbic pathway arises from the ventral tegmentum area and projects to the NAc and limbic system (AMG, HPC, inferior frontal cortex, and anterior cingulate gyrus).…”

Section: Disscussionmentioning

confidence: 99%

“…The mesolimbic pathway arises from the ventral tegmentum area and projects to the NAc and limbic system (AMG, HPC, inferior frontal cortex, and anterior cingulate gyrus). Dopamine depletion in PD could cause the dysfunction of the mesolimbic system and frontostriatal networks and subsequently involved the cognition, emotion, motivation, and behaviors (39,41). In PD with dementia, 18 F-DOPA uptake was significantly declined in the anterior cingulate areas, NAc, and right caudate nucleus, compared with those of PD without dementia (42).…”

Section: Disscussionmentioning

confidence: 99%

See 1 more Smart Citation

In Vivo Detection of Monoaminergic Degeneration in Early Parkinson Disease by ¹⁸F-9-Fluoropropyl-(+)-Dihydrotetrabenzazine PET

Lin

Hsiao

et al. 2013

J Nucl Med

View full text Add to dashboard Cite

PET with 18 F-9-fluoropropyl-(1)-dihydrotetrabenzazine ( 18 F-DTBZ), a novel radiotracer targeting vesicular monoamine transporter type 2 (VMAT2), has been proven as a useful imaging marker to measure dopaminergic integrity. Methods: The aim of this study was to evaluate the capability of 18 F-DTBZ PET in detecting the monoaminergic degeneration in early Parkinson disease (PD) in vivo. Seventeen age-matched healthy subjects and 30 PD patients at early stage of disease (duration of disease # 5 y) with mild and unilateral motor symptoms underwent 18 F-DTBZ PET scans. The severity of disease, including Unified Parkinson Disease Rating Scale and modified Hoehn and Yahr Stage (mHY), were recorded at off-medication states. The standardized volumes of interest were applied to the spatial normalized image for quantification analysis. The specific uptake ratios (SURs) were calculated according to the formula (specific volumes-of-interest counts/occipital cortex counts) 2 1. SUR measurements were summarized for each brain region. Results: The mean duration of disease in the PD group was 3.2 6 2.1 y (range, 0.5-5 y). The mean mHY was 1.0 6 0.1 (range, 1-1.5). The SURs of bilateral caudate, anterior putamen, posterior putamen, substantia nigra, and nucleus accumbens were significantly lower in PD patients than those of healthy subjects. The reduction of SURs was most severe in the contralateral (the brain regions that are located opposite to the symptomatic side) posterior putamen (281%), followed by the ipsilateral posterior putamen (267%). Receiver-operating-characteristic curve analysis showed that the SURs of the bilateral posterior putamen and contralateral anterior putamen had a sensitivity of 100% and specificity of 100% in differentiating PD patients from healthy subjects. Conclusion: 18 F-DTBZ PET was as an excellent tool for the early diagnosis of PD. The obvious decline of 18 F-DTBZ uptake in the ipsilateral (asymptomatic) striatum suggested that 18 F-DTBZ PET might serve as an in vivo biomarker to detect the monoaminergic degeneration in the premotor phase of PD.

show abstract

Section: Disscussionmentioning

confidence: 99%

Section: Disscussionmentioning

confidence: 99%

In Vivo Detection of Monoaminergic Degeneration in Early Parkinson Disease by ¹⁸F-9-Fluoropropyl-(+)-Dihydrotetrabenzazine PET

Lin

Hsiao

et al. 2013

J Nucl Med

View full text Add to dashboard Cite

show abstract

“…However, the link between the presence of specific neuropsychiatric symptoms and specific cognitive impairments needs to be reviewed as well as gaining a thorough understanding of the neural bases of specific symptoms, since prior studies used different methodologies and consequently produced inconsistent findings. Existing review articles on this topic focused mainly on a few neuropsychiatric symptoms and reviewed only either the neuropsychological or the neural correlates of those symptoms in PD, but did not cover the range of possible symptoms that can be observed in this disease and did not look for a parallel between brain atrophy or dysfunction and cognitive deficits within the same sample of patients [6][7][8][9][10][11][12].…”

Section: Introductionmentioning

confidence: 99%

Cognitive and neuroanatomical correlates of neuropsychiatric symptoms in Parkinson's disease: A systematic review

Alzahrani

Venneri

2015

Journal of the Neurological Sciences

View full text Add to dashboard Cite

show abstract

“…Apathy domains, which may miss or not fully capture a cognitive syndrome, and have been variable in their selection of cognitive measures and in their patient criteria (e.g., many studies exclude patients with dementia). Despite these limitations, apathy has been most consistently associated with poor executive functioning and depression has been most consistently associated with poor executive functioning and delayed episodic memory (for reviews, see [7,8]). However, the findings are quite variable.…”

Section: Introductionmentioning

confidence: 99%

The Unique and Combined Effects of Apathy and Depression on Cognition in Parkinson’s Disease

Cohen

Aita

Mari

et al. 2015

JPD

View full text Add to dashboard Cite

Abstract.Background: Apathy and depression are associated with poor cognition in patients with Parkinson's disease (PD). However, the cognitive signature of each syndrome is not well understood. The cognitive consequences of having apathy or depression, versus apathy and depression, are also unclear. Objective: This study investigated the unique and combined effects of apathy and depression on cognition in PD patients. Methods: PD patients were identified from a clinical research database as having self-reported apathy (n = 21), depression (n = 11), or both (n = 43). PD patients without apathy or depression served as the Control group (n = 49). The groups were of similar age, education, disease severity, age of symptom onset, and medication status. A multivariate analysis of variance (MANOVA) compared the groups on 17 neuropsychological test scores in the domains of attention, motor and psychomotor speed, construction, language, episodic memory, and executive functioning. Results: There was a significant overall effect of group: F(18,276) = 2.12, p = 0.006, η 2 p = 0.12. Univariate analyses and planned contrasts revealed medium-sized effects distinguishing only the control group and the group with both apathy and depression (η 2 p = 0.06-0.12) on measures of verbal fluency and manual, processing, and psychomotor speed. Conclusions: PD patients with apathy alone or depression alone did not perform worse than PD controls on neuropsychological tests. Patients with apathy and depression performed worse than controls, but only on speed-based measures. This suggests that apathy and depression are associated with the same or similar circuits as those of cognitive and motor speed.

show abstract

Affective symptoms and cognitive functions in Parkinson's disease

Cited by 57 publications

References 78 publications

In Vivo Detection of Monoaminergic Degeneration in Early Parkinson Disease by ¹⁸F-9-Fluoropropyl-(+)-Dihydrotetrabenzazine PET

In Vivo Detection of Monoaminergic Degeneration in Early Parkinson Disease by ¹⁸F-9-Fluoropropyl-(+)-Dihydrotetrabenzazine PET

Cognitive and neuroanatomical correlates of neuropsychiatric symptoms in Parkinson's disease: A systematic review

The Unique and Combined Effects of Apathy and Depression on Cognition in Parkinson’s Disease

Contact Info

Product

Resources

About

Affective symptoms and cognitive functions in Parkinson's disease

Cited by 57 publications

References 78 publications

In Vivo Detection of Monoaminergic Degeneration in Early Parkinson Disease by 18F-9-Fluoropropyl-(+)-Dihydrotetrabenzazine PET

In Vivo Detection of Monoaminergic Degeneration in Early Parkinson Disease by 18F-9-Fluoropropyl-(+)-Dihydrotetrabenzazine PET

Cognitive and neuroanatomical correlates of neuropsychiatric symptoms in Parkinson's disease: A systematic review

The Unique and Combined Effects of Apathy and Depression on Cognition in Parkinson’s Disease

Contact Info

Product

Resources

About

In Vivo Detection of Monoaminergic Degeneration in Early Parkinson Disease by ¹⁸F-9-Fluoropropyl-(+)-Dihydrotetrabenzazine PET

In Vivo Detection of Monoaminergic Degeneration in Early Parkinson Disease by ¹⁸F-9-Fluoropropyl-(+)-Dihydrotetrabenzazine PET